Can­del’s shares soar on Phase 3 prostate can­cer da­ta de­spite un­clear prospects

Can­del Ther­a­peu­tics’ vi­ral im­munother­a­py can­di­date passed a late-stage test in cer­tain pa­tients with prostate can­cer, send­ing its share price $CADL up around 60% even as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER